<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00830245</url>
  </required_header>
  <id_info>
    <org_study_id>CRCST-L-0005</org_study_id>
    <nct_id>NCT00830245</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Center for Solid Tumor, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korean Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Center for Solid Tumor, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with
      leptomeningeal carcinomatosis
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual rate
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytology negative conversion rate</measure>
    <time_frame>1 month, 2 months, 3 months, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic symptom improvement</measure>
    <time_frame>1 month, 2 months, 3 months, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (extra-cranial disease)</measure>
    <time_frame>2 months, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (brain)</measure>
    <time_frame>2 months, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 month, 2 months, 3 months, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>1 month, 2 months, 3 months, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic factors</measure>
    <time_frame>N-A</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leptomeningeal Carcinomatosis</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150mg/day (if no negative conversion --&gt; increment to 250mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150mg/day</description>
    <arm_group_label>Erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18

          2. Histologically or pathologically proven non-small cell lung cancer (NSCLC)

          3. Leptomeningeal carcinomatosis confirmed by CSF cytology

          4. A patients with EGFR mutation (including exon 19 deletion, L858R)

          5. ECOG performance status 0-3

          6. Expected life time more than at least 4 weeks

          7. A patients who signed the informed consent prior to the participation in the study

          8. Chemotherapy-naïve patient is eligible

          9. Previous EGFR TKI is allowed if this drug was not specifically used for CNS metastases

        Exclusion Criteria:

          1. A pregnant or lactating patient

          2. A patient of childbearing potential without being tested for pregnancy at baseline or
             with a positive test. (A postmenopausal woman with the amenorrhea period of at least
             12 months or longer is considered to have non-childbearing potential.)

          3. A man or woman of childbearing potential without the willingness to use a
             contraceptive measures during the study

          4. A patient with history of another malignant disease within past 3 years, except
             curatively treated basal cell carcinoma of the skin, cervical carcinoma in situ, and
             early gastric cancer

          5. A patient with active interstitial lung disease, except simple lymphangitic lung
             metastasis

          6. A patient with history of allergic reaction to gefitinib or erlotinib

          7. The following laboratory test results:

               -  Number of absolute neutrophils counts (ANC) &lt; 1.0ⅹ109/L

               -  Number of platelets &lt; 50 ⅹ109/L

               -  AST, ALT &gt; 2.5 ⅹupper limit of normal

               -  Total bilirubin &gt; 1.5 ⅹupper limit of normal

               -  Serum creatinine &gt; 1.5 ⅹupper limit of normal

          8. A patient with serious disease as followings

               -  Uncontrolled cardiac arrhythmia

               -  History of myocardial infarction within 6 months prior to the initiation of study

               -  Neurological or psychiatric disorder including dementia or uncontrolled seizure

          9. A patient who refused to sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dae Seog Heo</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <last_update_submitted>July 25, 2011</last_update_submitted>
  <last_update_submitted_qc>July 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dae Seog Heo/Professor</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>EGFR mutation</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>leptomeningeal carcinomatosis in EGFR mutation positive non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

